Thomas Evans, MD
Internal Medicine · Huntingdon, TNNPI 1841285228
Payments from drug & device makers
Across 306 payments — averaging $14.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$825
- AstraZeneca$755
- Amgen$553
- Novo Nordisk$505
- Merck$498
- Lilly USA, LLC$237
- plus $1K from 23 others
What the payments were for
- Food & beverage$4,534100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 73 | $825 |
| AstraZeneca | 43 | $755 |
| Amgen | 43 | $553 |
| Novo Nordisk | 29 | $505 |
| Merck | 40 | $498 |
| Lilly USA, LLC | 16 | $237 |
| Otsuka America Pharmaceutical, Inc. | 9 | $197 |
| Pfizer | 9 | $191 |
| Biogen | 4 | $96 |
| GSK | 5 | $86 |
| Sanofi-aventis U.S. LLC | 6 | $81 |
| Bayer | 3 | $75 |
| Boehringer Ingelheim | 4 | $57 |
| Abbott | 2 | $49 |
| Exact Sciences | 2 | $40 |
| Novartis | 3 | $38 |
| Neurocrine Biosciences, Inc. | 1 | $33 |
| Dexcom, Inc. | 2 | $32 |
| Sanofi Pasteur Inc. | 2 | $29 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
| Lundbeck LLC | 1 | $20 |
| Corvista Health, Inc. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
| Pacira Therapeutics, Inc. | 1 | $12 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$126
How this compares
$4,547 in reported general payments places this provider in the 85th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira PenAdalimumab | 13 | $176,448 |
| OzempicSemaglutide | 132 | $141,953 |
| EliquisApixaban | 162 | $109,788 |
| JardianceEmpagliflozin | 72 | $69,579 |
| EntrestoSacubitril/Valsartan | 104 | $61,060 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $56,354 |
| XifaxanRifaximin | 16 | $51,786 |
| LinzessLinaclotide | 64 | $49,012 |
| FarxigaDapagliflozin Propanediol | 54 | $41,036 |
| TrulicityDulaglutide | 22 | $36,083 |
| JanuviaSitagliptin Phosphate | 28 | $31,908 |
| Tresiba Flextouch U-100Insulin Degludec | 58 | $31,677 |
| Repatha SureclickEvolocumab | 49 | $30,406 |
| Tresiba Flextouch U-200Insulin Degludec | 32 | $29,318 |
| RybelsusSemaglutide | 30 | $28,335 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $505 | $170,288162 claims |
| PfizerEliquis | $191 | $109,788162 claims |
| Boehringer IngelheimJardiance, Tradjenta | $57 | $86,224109 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Arexvy, Incruse Ellipta | $86 | $85,166131 claims |
| AbbVieLinzess, Vraylar | $825 | $76,47084 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort | $755 | $74,085103 claims |
| MerckJanuvia, Janumet, Janumet Xr | $498 | $62,01771 claims |
| NovartisEntresto | $38 | $61,060104 claims |
| Lilly USA, LLCTrulicity | $237 | $36,08322 claims |
| Johnson & JohnsonXarelto | $15 | $28,01935 claims |
| AmgenProlia | $553 | $23,75614 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $11 | $9,18511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Huntingdon
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
- Rick WhilesBristol$1.5M
- John AndersonNashville$1.5M
- David MorinKingsport$1.4M
- John KirbyJefferson City$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.